Market closed
Bionano Genomics/$BNGO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Bionano Genomics
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
Ticker
$BNGO
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
344
Website
Bionano Genomics Metrics
BasicAdvanced
$28M
Market cap
-
P/E ratio
-$4.18
EPS
2.41
Beta
-
Dividend rate
Price and volume
Market cap
$28M
Beta
2.41
52-week high
$2.27
52-week low
$0.26
Average daily volume
2.6M
Financial strength
Current ratio
1.629
Quick ratio
0.68
Long term debt to equity
7.227
Total debt to equity
34.318
Interest coverage (TTM)
-15.83%
Management effectiveness
Return on assets (TTM)
-32.64%
Return on equity (TTM)
-138.33%
Valuation
Price to revenue (TTM)
0.393
Price to book
0.26
Price to tangible book (TTM)
0.41
Price to free cash flow (TTM)
-0.136
Growth
Revenue change (TTM)
16.08%
Earnings per share change (TTM)
-14.09%
3-year revenue growth (CAGR)
40.43%
3-year earnings per share growth (CAGR)
18.50%
What the Analysts think about Bionano Genomics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Bionano Genomics stock.
Bionano Genomics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Bionano Genomics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Bionano Genomics News
AllArticlesVideos
Optical Genome Mapping Market to Witness 26.76% CAGR During 2024-2030 - Consumables and Reagents to Register High Growth - Bionano Genomics, Nucleome Informatics, and Praxis Genomics Dominate the Industry
GlobeNewsWire·5 days ago
Bionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
GlobeNewsWire·1 week ago
Bionano Adjourns Special Meeting of Stockholders to November 27, 2024
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Bionano Genomics stock?
Bionano Genomics (BNGO) has a market cap of $28M as of November 08, 2024.
What is the P/E ratio for Bionano Genomics stock?
The price to earnings (P/E) ratio for Bionano Genomics (BNGO) stock is 0 as of November 08, 2024.
Does Bionano Genomics stock pay dividends?
No, Bionano Genomics (BNGO) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Bionano Genomics dividend payment date?
Bionano Genomics (BNGO) stock does not pay dividends to its shareholders.
What is the beta indicator for Bionano Genomics?
Bionano Genomics (BNGO) has a beta rating of 2.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.